April 9th 2024
New study finds trial enrollment was highest at NCI-designated cancer centers. Researchers said more needs to be done to enroll patients from community cancer sites.
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Updates: Moderna COVID-19 Vaccine EUA Caps Busy Week
December 20th 2020The second mRNA vaccine, which does not need the extreme refrigeration of the Pfizer product, began rolling out of a warehouse in Mississippi early Sunday. Friday brought other late-year approvals in cancer treatment.
Read More
Improving Cancer Research Priorities in Light of COVID
November 30th 2020The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.
Read More
Radiation Oncologists Urge Congress to Advance Bills That Protect Patient Access to Cancer Care
November 26th 2020Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.
Read More
Bringing CAR-T Cell Therapy to the Community
November 23rd 2020In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.
Read More
5 Changes That Should be Made in Oncology
September 25th 2020COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.
Read More
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Read More